Among privately insured patients, there was a doubling in the use of GLP-1 RAs as antiobesity treatment from 2022 to 2023, with a simultaneous 25.6% decrease in the rate of metabolic bariatric surgery ...

Smoothie King just launched its GLP-1 Support Menu with five specific smoothie blends to help support the journey of individuals using GLP-1 weight loss medications like Ozempic and Wegovy – and ...

For Sprackling, the key to consumers benefiting from GLP-1 medications is responsible use rather than viewing them as a quick ...

"The sales growth is driven by increasing demand for our GLP-1-based diabetes and obesity treatments, and we are serving more ...

Weight-loss and diabetes drugmaker Novo Nordisk on Wednesday posted third-quarter operating profit in line with expectations ...

As the GLP-1 class has taken over in recent years, a once-fringe conference has come into the spotlight for the biopharma industry. ObesityWeek, which started in 2013, attracted ...

Novo Nordisk's Q3 2024 report highlights a 21% YoY sales increase with strong gains in GLP-1 diabetes and obesity drugs but ...

Novo Nordisk is the company that makes the Ozempic and Wegovy drugs, part of the wildly popular GLP-1 class of drugs that have proven effective in reducing weight and treating diabetes. Demand has ...

Nutritionists say there’s an easy, natural and cheaper way to get the same results as prescription weight loss drugs.

Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 ...

COPENHAGEN (Reuters) -Weight-loss and diabetes drugmaker Novo Nordisk on Wednesday posted third-quarter operating profit in line with expectations and narrowed its full-year sales and profit guidance ...